Skip to main content
. 2009 Feb 17;32(5):926–931. doi: 10.2337/dc08-1979

Table 1.

Descriptive characteristics of women (n = 984) with diabetes by category of CCI measuring phobic anxiety

CCI (0–16 points)
P trend
0 or 1 2 or 3 ≥4
n 288 318 378
Demographic
    Age (years) 59.3 ± 6.5 58.8 ± 6.7 58.5 ± 6.7 0.13
    BMI (kg/m2) 29.9 ± 6.4 29.2 ± 6.1 30.6 ± 6.4* 0.10
    Physical activity (METs/week) 12.6 ± 15.2 12.4 ± 16.9 10.6 ± 14.2 0.10
    Total energy intake (kcal) 1,742 ± 503 1,784 ± 514 1,796 ± 537 0.21
    Alcohol (g/day) 3.0 ± 7.4 2.7 ± 6.6 2.8 ± 8.6 0.68
    Current smoker 29 (10.2) 47 (14.9) 60 (15.9) 0.04
    Caucasian race 285 (98.9) 307 (96.5) 364 (96.3) 0.10
    Married 228 (83.2) 249 (82.2) 294 (80.6) 0.38
    Education (Bachelor's degree) 88 (32.2) 70 (23.2) 71 (19.4) 0.0002
    Full-time employment 82 (30.0) 76 (25.1) 98 (26.9) 0.43
Medical history
    Hypertension 106 (36.8) 128 (40.3) 172 (45.5) 0.02
    Hypercholesterolemia 123 (42.7) 119 (37.4) 153 (40.5) 0.63
    Duration of diabetes ≥2 years 126 (43.8) 143 (45.0) 131 (34.7) 0.01
    Family history of diabetes 149 (51.7) 164 (51.6) 198 (52.4) 0.86
    Insulin 60 (20.8) 59 (18.6) 69 (18.3) 0.42
    Oral diabetes medication 67 (23.3) 81 (25.5) 68 (18.0) 0.08
    A1C (%) 7.0 ± 1.8 6.9 ± 1.7 6.8 ± 1.7 0.12
Medications
    Aspirin 133 (46.2) 146 (45.9) 158 (41.8) 0.24
    Postmenopausal hormones 101 (35.1) 106 (33.3) 120 (31.8) 0.37
    Thiazide diuretics 78 (27.1) 110 (35.6) 134 (35.5) 0.03
    Other hypertension medication 21 (7.3) 29 (9.1) 48 (12.7) 0.02
    β-Blocker 40 (13.9) 51 (16.0) 70 (18.5) 0.11
ACE inhibitor 25 (8.7) 23 (7.2) 44 (11.6) 0.16
    Calcium channel blocker 6 (2.1) 21 (6.6) 24 (6.4) 0.02
    Cholesterol-lowering medication 17 (5.9) 15 (4.7) 13 (3.4) 0.13
Biomarkers
    Adiponectin (μg/ml) 5.3 (1.0–31.7) 6.1 (1.3–38.4) 5.4 (1.2–41.8) 0.35
    Leptin (ng/ml) 44.0 (1.6–144) 40.1 (1.5–229) 47.7 (2.0–162)* 0.006
    CRP (mg/l) 3.5 (0.6–34) 3.4 (0.7–35) 3.9 (0.7–35) 0.06
    sE-selectin (ng/ml) 59.0 (16.2–229) 55.9 (18.8–327) 61.0 (14.2–525)* 0.20
    sICAM-1 (ng/dl) 290 (130–799) 285 (100–849) 305 (9.0–1,074)* 0.02
    sTNF-αRII (pg/ml) 2,387 (939–6,946) 2,310 (1,005–6,861) 2,496 (1,046–9,355)* 0.03

Data are means ± SD, n (%), or median (range).

*Significantly different from group 2 (Bonferroni-adjusted P value <0.05).

†Significantly different from group 1 (Bonferroni-adjusted P value <0.05).